CompanyIntelligence | Enzon Pharmaceuticals, Inc.

The Consus Group provides critical intelligence for the
business, investor, and legal communities.

Documents can be downloaded immediately after purchase. Complete your order by clicking the Add-to-Cart button.

$36	Subscribers Preview	2002	Certificate of Designation, Preferences and Rights of Series B Preferred Stock	Enzon, Inc.	Enzon Pharmaceuticals, Inc.
$36	Subscribers Preview	2002	Certificate of Elimination Eliminating Classes of Series B, C and D Convertible Preferred Stocks	Enzon, Inc.	Enzon Pharmaceuticals, Inc.
$30	Subscribers Preview	2002	Enzon Acquires Abelcet(R) North American Business from Elan	Enzon, Inc.; Elan	Enzon Pharma
$40	Subscribers Preview	2004	Enzon and Inex Present Promising Follow-Up Data at American Society of Clinical Oncology Showing Onco TCS Potential in First-Line Lymphoma	Enzon Pharmaceuticals, Inc.
$37	Subscribers	2004	Enzon and INEX Sign Commercialization Partnership for Oncology Drug Onco TCS	Elan; Enzon Pharma	INEX Pharma
$37	Subscribers Preview	2004	Enzon Announces Nektar Pegylation Agreement	Nektar Therapeutics; Enzon Pharma	Pfizer
$39	Subscribers Preview	2002	Enzon Completes Acquisition of Abelcet(R) North American Business from Elan	Enzon, Inc.; Elan	Enzon Pharma
$37	Subscribers Preview	2003	Enzon Pharmaceuticals Reports Third Quarter Financial	Elan; Enzon Pharma	NPS Pharma
$41	Subscribers Preview	2004	Enzon Provides Clinical Updates on Three Oncology Candidates At Annual Meeting of American Society of Clinical Oncology	Enzon Pharmaceuticals, Inc.
$30	Subscribers Preview	2003	Enzon Reports First Quarter Results	Enzon Pharmaceuticals, Inc.
$37	Subscribers Preview	2004	Enzon Reports Fourth Quarter and Fiscal Year Results	Enzon Pharmaceuticals, Inc.	NPS Pharmaceuticals, Inc.
$35	Subscribers Preview	2003	Enzon Reports Fourth Quarter and Fiscal Year Results	Elan; Enzon Pharma	NPS Pharma
$36	Subscribers Preview	2004	Enzon Reports Second Quarter Financial Results	Elan; Enzon Pharma	SkyePharma
$33	Subscribers Preview	2004	Enzon Reports Third Quarter Financial Results	Enzon Pharmaceuticals, Inc.
$35	Subscribers Preview	2003	Enzon Updates Its Financial Outlook for The Fiscal Year Ending June 30, 2004	Enzon Pharmaceuticals, Inc.
$36	Subscribers	2002	Enzon, Inc. Adopts Stockholders' Rights Plan	Enzon Pharmaceuticals, Inc.
$41	Subscribers Preview	2004	For Immediate Release	Amgen; Enzon Pharma	NPS Pharma
$39	Subscribers Preview	2003	Guaranteed Convertible Notes	aaiPharma; Acusphere; Allergan	Amarin 2 3 4 5 6 2 2
$33	Subscribers Preview	2003	Independent Directors' Compensation Arrangement	Enzon Pharmaceuticals, Inc.
$37	Subscribers Preview	2004	Inex and Enzon Announce FDA Acceptance of Onco TCS New Drug Application	Enzon Pharmaceuticals, Inc.